High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated […]
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated: Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and […]
Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.
Boston Scientific enters this update cycle with no changes to its current price target, leaving expectations exactly where analysts previously set them. With no new analyst commentary on the stock, the story is less about fresh opinions and more about how existing views are holding steady for now. Ahead, you will see how to track this kind of quiet reset and what it can signal as the narrative around Boston Scientific continues to evolve. Stay updated as the Fair Value for Boston Scientific...
Boston Scientific (NYSE:BSX) reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The trial assessed safety and effectiveness of SEISMIQ 4CE in treating severely calcified coronary artery disease, a complex area of interventional cardiology. This clinical milestone relates to Boston Scientific's coronary portfolio and has not been the focus of recent coverage that centered on Watchman and product...
Boston Scientific has considerably underperformed its sector peers recently, yet analysts remain highly optimistic about the stock’s prospects.
Boston Scientific was down about 0.7% at close, while Lowe's Companies ended the session 3% lower, and Conagra Brands fell by about 1.3%.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Quanta Services, Roblox, and Boston Scientific announced share buybacks totaling $6 billion, each under different market conditions and for different strategic reasons.
Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. An Investing Club member sought Cramer’s advice about choosing the best medical equipment maker out of the three: Abbott Labs, Boston Scientific, and Medtronic. He replied: Boston Scientific had a very […]
Medtronic plc (NYSE:MDT) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. Cramer highlighted the company’s share price performance, as he said: Wednesday morning, Medtronic reports. Speaking of jarring, this long-term winner’s become a short-term loser with the stock down 23% year to date. […]
Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform. This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth […]
Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.
Medtronic has underperformed the Nasdaq Composite, and analysts remain somewhat optimistic about the stock’s outlook.
Analyst downgrades, weak outlooks, and management changes added pressure.
Boston Scientific (BSX) stock has been under pressure after management flagged slowing growth in its Watchman heart implant business, a key contributor to earnings. The company reaffirmed full year guidance and is facing fresh competition in left atrial appendage closure. See our latest analysis for Boston Scientific. The sharp reset in expectations for Watchman growth has coincided with a steep share price selloff, with the stock down 37.1% over three months and the 1 year total shareholder...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.
Sales of a key product line will likely be flat this quarter and next, company management said.
Boston Scientific stock has more questions than answers. Shares of the medical device maker dropped have about 14% this week to about $49 after management said growth of its Watchman product, an implant that reduces the risk of stroke in patients with non-valvular atrial fibrillation (AFib), is slowing. The company stood by its financial guidance, but the market clearly has larger concerns.
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
Boston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
